Evercore ISI analyst Gavin Clark-Gartner lowered the firm’s price target on Dianthus (DNTH) to $120 from $122 and keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus price target raised to $125 from $123 at Raymond James
- Dianthus reports Q1 EPS (85c), consensus ($1.10)
- Dianthus treatment of myasthenia gravis gets orphan status
- Dianthus Therapeutics: Best-in-Class C1s Antibody Claseprubart and Strong Execution Support Outperform Rating
- Bullish View on Dianthus: Claseprubart’s Differentiated Complement Inhibition and Underappreciated Bifunctional Pipeline Drive Buy Rating